A prospective cohort study published in Scientific Reports found that early reductions in hepatitis B surface antigen (HBsAg) levels predict the response to entecavir therapy in genotype B-infected or C-infected patients with chronic hepatitis B (HBV).1
Treatment response to peginterferon can be predicted by the absolute reduction in HBsAg levels, as well as the decline in levels after 3 or 6 months of treatment, in hepatitis B e-antigen (HBeAg)-positive and -negative patients, respectively.2,3 In nucleos(t)ide analog (NA) therapy, this reduction is slower and less pronounced.4 In HBeAg-positive patients, HBsAg loss is associated with a rapid decline in HBsAg levels during the first year of treatment with telbivudine (≥0.5 log10 IU/mL at month 6 or ≥1.0 log10IU/mL at month 12), and a reduction of ≥1.0 log10 IU/mL at week 24 of tenofovir therapy.5,6
However, the kinetics of HBsAg levels in early NA treatment, as well as optimal cutoffs and time points to define HBsAg reduction during treatment, remain unclear. In addition, the link between “early HBsAg decline and the therapeutic outcomes during long-term NA treatment is controversial,” wrote the investigators.
Note: It’s important to read the entire article. It states that alcohol use and smoking can contribute to Parkinson’s disease. Studies have found that people with hepatitis C (as a group) are more likely to drink more alcohol and smoke cigarettes. Furthermore, prior studies have not found a link between hepatitis B and Parkinson’s disease. I think this study is interesting but we need larger more definitive research. Alan
MINNEAPOLIS – The viruses hepatitis B and C may both be associated with an increased risk of Parkinson’s disease, according to a study published in the March 29, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. The hepatitis virus affects the liver.
According to the Centers for Disease Control and Prevention (CDC), it is estimated that anywhere from 850,000 to 2.2 million people in the United States have chronic hepatitis B virus infection and anywhere from 2.7 to 3.9 million people have chronic hepatitis C. While both can lead to serious illness, many people have few symptoms and do not realize they have the virus, especially at first.
Hepatitis B is spread through contact with blood and body fluids of an infected person, such as unprotected sex, sharing needles, getting a tattoo or piercing with unsterilized tools or sharing razors or toothbrushes with an infected person.